B
Bullisch
Bullisch · 25%MLTX
$48.66
Szenariopreis
$9.550
-0.661 (-6.92%)Zum Schluss
Loading chart…
- Hoch
- 10.340
- Eröffnung
- 10.340
- Volumengewichteter Durchschnittskurs
- 9.78
- Volumen
- 1.38M
- Marktkap.
- 2.62B
- Tief
- 9.460
- Umsatz
- 13.51M
- EV/EBITDA, TTM
- 0.00
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
KI-Analyse of MoonLake Immunotherapeutics (MLTX)
HaltenMoonLake Immunotherapeutics is currently not a strong buy due to its high volatility and recent price decline, despite positive catalysts. The current price is $10.82, with a 5-day change of -5.17% and an RSI of 29.259 indicating oversold conditions. The company has a significant cash position of $537 million, which supports ongoing operations and clinical trials, but it also reported a substantial net loss of $69.7 million in Q1 2026, highlighting financial risks.
Bewertungskennzahlen
Das aktuelle erwartete KGV von MoonLake Immunotherapeutics (MLTX) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -20.01.
Alphio-AI-Kursszenarien für MLTX
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die MLTX halten
Event-Zeitleiste
News
9.009-11stocktwitsMoonLake Plans FDA Filing for Sonelokimab Approval
9.508-10stocktwitsMoonLake Reports Positive Phase 3 Results and Narrower Q2 Loss
8.508-03stocktwitsMoonLake Immunotherapeutics Investor Day Highlights
8.507-13stocktwitsMerck's Key Drug Faces Patent Cliff Ahead
5.007-03FoolCFO Sells 39,120 Shares of MoonLake Immunotherapeutics
MLTX FAQ – beantwortet von Alphio AI
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
MoonLake Immunotherapeutics is currently not a strong buy due to its high volatility and recent price decline, despite positive catalysts. The current price is $10.82, with a 5-day change of -5.17% and an RSI of 29.259 indicating oversold conditions. The company has a significant cash position of $537 million, which supports ongoing operations and clinical trials, but it also reported a substantial net loss of $69.7 million in Q1 2026, highlighting financial risks.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.